Efficacy of virtual reality exposure therapy

Referències bibliogràfiques

• American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. DSM-IV-TR. Washington, DC: Author (Spanish translation, Barcelona: Masson, 2002).
• American Psychiatric Association (2004). Treating Panic Disorder. A Quick Reference Guide. Washington, DC: Author.
• Beck, A., Epstein, N., Brown, G., and Steer, R. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology, 56, 893-897.
• Bienvenue, O.J., Onyike, C.U., Stein, M.B., Chen, L., Samuels, J., Nestadt, G., and Eaton, W.W. (2006). Agoraphobia in adults: Incident and longitudinal relationship with panic. The British Journal of Psychiatry, 188, 432-438.
• Botella, C., Villa, H., García-Palacios, A., Quero, S., Baños, R.M., Alcaniz, M., and Riva, G. (2007). Virtual reality exposure in the treatment of panic disorder and agoraphobia: A controlled study. Clinical Psychology & Psychotherapy, 14, 164-175.
• Bradwejn, J., Ahokas, A., Stein, D.J., Salinas, E., Emilien, G., and Whitaker, T. (2005). Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. The British Journal of Psychiatry, 187, 352-359.
• Chambless, D.L., Caputo, G.C., Bright, P., and Gallagher, R. (1984). Assessment of fear in agoraphobics: The body sensations questionnaire and the agoraphobic cognitions questionnaire. Journal of Consulting and Clinical Psychology, 52, 1090-1097.
• Choi, Y., Fyer, A.J., and Lipsitz, J.D. (2007). Treatment of specific phobia in adults. Clinical Psychology Review, 27, 266-286.
• Choi, Y.H., Vincelli, F., Riva, G., Wiederhold, B.K., Lee, J.H., and Park, K.H. (2005). Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia. Cyberpsychology and Behavior, 8, 387-393.
• Comeche, M.I., Díaz, M.I., and Vallejo, M.I. (1995). Cuestionarios, Inventarios y Escalas: Ansiedad, Depresión y Habilidades Sociales. Madrid: Fundación Universidad-Empresa.
• De Abajo, F.J. and García-Rodríguez, L.A. (2008). Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Archives of General Psychiatry, 65, 795-803.
• De Carvalho, M.R., Freire, R.C., and Nardi, A.E. (2010). Virtual reality as a mechanism for exposure therapy. The World Journal of Biological Psychiatry, 11, 220-230.
• Echeburúa, E. and Becoña, E. (2000). Guía de Tratamientos Psicológicos. Madrid: Dykinson.
• Echeburúa, E. and Corral, P. (2001). Eficacia de las terapias psicológicas: De la investigación a la práctica clínica. International Journal of Clinical and Health Psychology, 1, 181-201.
• Echeburúa, E., Corral, P., García, E., Páez, D., and Borda, M. (1992). Un nuevo Inventario de Agorafobia (IA). Análisis y Modificación de Conducta, 18, 101-123.
• Ferguson, J.M., Khan, A., Mangano, R., Entsuah, R., and Tzanis, E. (2007). Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. The Journal of Clinical Psychiatry, 68, 58-68.
• Furukawa, T.A., Watanabe, N., and Churchill, R. (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. The British Journal of Psychiatry, 188, 305-312.
• Gregg, L. and Tarrier, N. (2007). Virtual reality in mental health: A review of the literature. Social Psychiatry and Psychiatric Epidemiology, 42, 343-354.
• Hagenaars, M.A., van Minnen, A., and de Rooij, M. (2010). Cognitions in prolonged exposure therapy for posttraumatic stress disorder. International Journal of Clinical and Health Psychology, 10, 421-434.
• Kessler, R.C. and Üstün, T.B. (2004). The World Mental Health (WMH) Survey Initiave Version of the World Health Organization, Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research, 13, 93-121.
• Kjernisted, K. and McIntosh, D. (2007). Venlafaxine extended release (XR) in the treatment of panic disorder. Therapeutics and Clinical Risk Management, 3, 59-69.
• Meyerbröker, K. and Emmelkamp, P.M. (2010). Virtual reality exposure therapy in anxiety disorders: A systematic review of process-and-outcomes studies. Depression and Anxiety, 27, 933-944.
• Mitte, K. (2005). A meta-analysis of the efficacy of psycho and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders, 88, 27-45.
• Mochcovitch, M.D. and Nardi, A.E. (2010). Selective serotonin-reuptake inhibitors in the treatment of panic disorder: A systematic review of placebo-controlled studies. Expert Review of Neurotherapeuthics, 10, 1285-1293.
• Montero I. and León, O. (2007). A guide for naming research studies in Psychology. International Journal of Clinical and Health Psychology, 4, 505-520.
• Pae, C.U. and Patkar, A.A. (2007). Paroxetine: Current status in psychiatry. Expert Review of Neurotherapeuthics, 7, 107-120.
• Peñate, W., Pitti, C.T., Bethencourt, J.M., de la Fuente, J., and Gracia, R. (2008). The effects of a treatment based on the use of virtual reality exposure and cognitive-behavioral therapy applied to patients with agoraphobia. Preliminary results. International Journal of Clinical and Health Psychology, 8, 5-22.
• Pérez-Ara, M.A., Quero, S., Botella, C., Baños, R., Andreu-Mateu, S., García-Palacios, A., and Bretón-López, J. (2010). Virtual reality interoceptive exposure for the treatment of panic disorder and agoraphobia. In B. K. Wiederhold, G. Riva, and S. I. Kim (Eds.), Studies in health technology and informatics (vol. 154, pp. 77-81). Amsterdam: IOS Press.
• Pitti, C.T., Peñate, W., de la Fuente, J., Bethencourt, J.M., Acosta, L., Villaverde, M.L., and Gracia, R. (2008). Agoraphobia: Combined treatment & virtual reality. Preliminary results. Actas Españolas de Psiquiatría, 36, 94-101.
• Pollack, M., Lepola, U., Koponen, H., Simon, N.M., Worthington, J.J., Emilien, G., Tzanis, E., Salinas, E., Whitaker, T., and Gao, B. (2007). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety, 24, 1-14.
• Pollack, M., Mangano, R., Entsuah, R., Tzanis, E., and Simon, N.M. (2007). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology, 194, 233-242.
• Pull, C.B. and Damsa, C. (2008). Pharmacotherapy of panic disorder. Neuropsychiatric Disease and Treatment, 4, 779-795.
• Tsao, J.C., Mystkowsi, J.L., Zucker, B.G., and Craske, M.G. (2005). Impact of cognitive-behavioral therapy for panic disorder on comorbidity: A controlled investigation. Behaviour Research and Therapy, 43, 959-970.
• Ramos-Álvarez, M.M., Moreno-Fernández, M.M., Valdés-Conroy, B., and Catena, A. (2008). Criteria of the peer-review process for publication of experimental and quasi-experimental research in Psychology: A guide for creating research papers. International Journal of Clinical and Health Psychology, 8, 751-764.
• Sánchez-Meca, J., Rosa-Alcázar, A., Marín-Martínez, F., and Gómez-Conesa, A. (2010). Psychological treatment of panic disorder with or without agoraphobia: A meta-analysis: Clinical Psychology Review, 30, 37-50.
• Sanz, J. and Navarro, M.E. (2003). Propiedades psicométricas de una versión española del inventario de ansiedad de Beck (BAI) en estudiantes universitarios. Ansiedad y Estrés, 9, 59-89.
• Vincelli, F., Anolli, L., Bouchard, S., Wiederhold, B.K., Zurloni, V., and Riva, G. (2003). Experiential cognitive therapy in the treatment of panic disorders with agoraphobia: A controlled study. Cyberpsychology and Behavior, 6, 321-328.
• World Health Organization (1992). ICD-10: International Statistical Classification of Diseases and Related Health Problems. Geneve: Author.